Comparison of different methods of intracerebral administration of radioiododeoxyuridine for glioma therapy using a rat model

British Journal of Cancer

Volumn 82, Issue 1, 2000, Pages 74-80

  Mairs, R J ^a   Wideman, C L ^b   Angerson, W J ^a   Whateley, T L ^c   Reza, M S ^c   Reeves, J R ^a   Robertson, L M ^a   Neshasteh Riz, A ^a   Rampling, R ^a   Owens, J ^d   Allan, D ^e   Graham, D I ^e  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^d WESTERN INFIRMARY   (United Kingdom)

^e NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

Glioma; Intracerebral therapy; Radioiododeoxyuridine; Rat; Sustained release

Indexed keywords

IDOXURIDINE; POLYGLACTIN; RADIOACTIVE IODINE;

ANIMAL CELL; ARTICLE; AUTORADIOGRAPHY; BRAIN; CANCER CELL; CELL LINE; CELL PROLIFERATION; DNA SYNTHESIS; DRUG DELIVERY SYSTEM; DRUG UPTAKE; FEMALE; GLIOMA; MALE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT;

EID: 0033989806     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.1999.0879     Document Type: Article

References (27)

1. 123I]iodo-2′-deoxyuridine in the radiotherapy of an early ascites tumor model. Int J Radiat Oncol Biol Phys 21: 1541-1551
2. Beutler AS, Banek MS, Wedekind D and Hedrich HJ (1999) Tumor gene therapy made easy: allogeneic major histocompatibility complex in the C6 rat glioma model. Human Gene Ther 10: 95-101
3. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brein S, Mohr G, Muller P, Morawetz R and Schold SC (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345: 1008-1012
4. Cruickshank GS (1997) The use of SPECT in the analysis of brain tumours. In: SPECT Imaging of the Brain, Duncan R (ed), pp. 161-178. Kluwer Academic: Dodrecht
5. Cunningham SH, Mairs RJ, Wheldon TE, Welsh PC, Vaidyanathan G and Zalutsky MR (1998) Radiotoxicity to neuroblastoma cells and spheroids of beta-, alpha-and Auger electron-emitting conjugates of benzylguanidine. Br J Cancer 77: 2061-2068
6. 125I in mammalian cells. Radiat Res 111: 305-318
7. 125I]iodo-2′-deoxyuridine in the radiotherapy of brain tumors in rats. J Nucl Med 39: 1148-1154
8. 125I]iodo-2′-deoxyuridine in the radiotherapy of solid CNS tumors in rats. Acta Oncol 35: 935-939
9. 123I]iodo-2′-deoxyuridine in a patient with a hrain tumor. J Nucl Med 37: 19S-22S
10. Klecker RW Jr, Jenkins JF, Kinsella TJ, Fine RL, Strong JM and Collins JM (1985) Clinical pharmacology of 5-iodo-2′-deoxyuridine and 5-iodo-uracil and endogenous pyrimidine modulation. Clin Pharmacol Ther 38: 45-51
11. 211At]astato-2′-deoxyuridine in human cancer cells. Int J Radiat Biol 72: 79-90
12. Martin RF and Haseltine WA (1981) Range of radiochcmieal damage to DNA with decay of iodine-125. Science 213: 896-898
13. Menei P, Boisdron-Celle M, Croue A, Guy G, Benoit JP (1996) Effect of stereotaxic implantation of biodegradable 5-fluorouracil-loaded microspheres in healthy and C6 glioma-bearing rats. Neurosurgery 39: 117-123
14. Neshastch-Riz A, Angerson WJ, Reeves JR, Smith G, Rampling R and Mairs RJ (1997) Incorporation of iododeoxyuridine in multicellular glioma spheroids: implications for DNA-targeted radiotherapy using Auger electron emitters. Br J Cancer 75: 493-499
15. 131I]IUdR to human glioma cells in monolayer or spheroid culture: effect of proliferative heterogeneity and radiation cross-fire. Br J Cancer 77: 385-390
16. O'Donoghue JA and Wheldon TE (1996) Targeted radiotherapy using Auger electron emitters. Phys Med Biol 41: 1973-1979
17. Olivi A, Ewend MG, Utsuki T, Tyler B, Domb AJ, Brat DJ and Brem H (1996) Interstitial delivery of carboplatin via biodegradable polymers is effective against experimental glioma in the rat. Cancer Chem Pharmacol 39: 90-96
18. 125IUdR loaded biodegradable microspheres for controlled delivery to the brain. J Microencapsulation 15: 789-801
19. Reza S and Whateley TL (1999) Biodegradable thin films for sustained delivery to the brain. Drug Delivery (in press)
20. 125I]iodo-2′-deoxyuridine in a rat model of leptomeningcal metastases. J Nucl Med 38: 386-390
21. Sipos EP, Tyler B, Piantadosi S, Burger PC and Brein H (1997) Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Cancer Chem Pharmacol 39: 383-389
22. 211At]astato-2′-deoxyuridine, an α-particle-emitting endoradiotherapeutic agent undergoing DNA incorporation. Cancer Res 56: 1204-1209
23. Vertosick FT, Selker RG, Grossman SJ and Joyse JM (1994) Correlation of thallium-201 single photon emission computed tomography and survival after treatment failure in patients with malignant glioma. Neurosurgery 34: 396-401
24. Walicka MA, Vaidyanathan G, Zalutsky MR, Adelstein SJ and Kassis AI (1998) Survival and DNA damage in chinese hamster V79 cells exposed to alpha particles emitted by DNA-incorporaled astatine-211. Radiat Res 150: 263-268
25. Whateley TL, Rampling R, Robertson L, Crossan IM, Fallon PA, Plumb JA and Kerr DJ (1995) Biodegradable systems for sustained delivery of drugs to brain-tumors. J Cell Bioschem S19A: p. 178.
26. Williams JA, Dillehay LE, Tabassi K, Sipos E, Fahlman C and Brem H (1997) Implantable biodegradable polymers for IUdR radiosensitisation of experimental human malignant glioma. J Neurooncol 32: 181-192
27. Zhu J, Zhang L, Hanisch UK, Felgner PL and Reszka RA (1996) Continuous intracerebral gene delivery system for in vivo liposome-mediated gene therapy. Gene Ther 3: 472-476